Future Screening Prospects for Ovarian Cancer

Current diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diag...

Full description

Bibliographic Details
Main Authors: Diana Žilovič, Rūta Čiurlienė, Rasa Sabaliauskaitė, Sonata Jarmalaitė
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/15/3840
id doaj-ec45e0467fc14d449a36a18fff63ccc4
record_format Article
spelling doaj-ec45e0467fc14d449a36a18fff63ccc42021-08-06T15:20:40ZengMDPI AGCancers2072-66942021-07-01133840384010.3390/cancers13153840Future Screening Prospects for Ovarian CancerDiana Žilovič0Rūta Čiurlienė1Rasa Sabaliauskaitė2Sonata Jarmalaitė3Life Sciences Center, Institute of Biosciences, Vilnius University, Saulėtekio Avenue 7, LT-10222 Vilnius, LithuaniaOncogynecology Department, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaLaboratory of Genetic Diagnostic, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaLaboratory of Clinical Oncology, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaCurrent diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diagnostic and screening methods are urgently needed for early OC diagnosis. Liquid biopsies have been considered as a new noninvasive and promising method, using plasma/serum, uterine lavage, and urine samples for early cancer detection. We analyzed recent studies on molecular biomarkers with specific emphasis on liquid biopsy methods and diagnostic efficacy for OC through the detection of circulating tumor cells, circulating cell-free DNA, small noncoding RNAs, and tumor-educated platelets.https://www.mdpi.com/2072-6694/13/15/3840ovarian cancerliquid biopsiesuterine lavagehigh-throughput methodsNGS-based multigene panels
collection DOAJ
language English
format Article
sources DOAJ
author Diana Žilovič
Rūta Čiurlienė
Rasa Sabaliauskaitė
Sonata Jarmalaitė
spellingShingle Diana Žilovič
Rūta Čiurlienė
Rasa Sabaliauskaitė
Sonata Jarmalaitė
Future Screening Prospects for Ovarian Cancer
Cancers
ovarian cancer
liquid biopsies
uterine lavage
high-throughput methods
NGS-based multigene panels
author_facet Diana Žilovič
Rūta Čiurlienė
Rasa Sabaliauskaitė
Sonata Jarmalaitė
author_sort Diana Žilovič
title Future Screening Prospects for Ovarian Cancer
title_short Future Screening Prospects for Ovarian Cancer
title_full Future Screening Prospects for Ovarian Cancer
title_fullStr Future Screening Prospects for Ovarian Cancer
title_full_unstemmed Future Screening Prospects for Ovarian Cancer
title_sort future screening prospects for ovarian cancer
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-07-01
description Current diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diagnostic and screening methods are urgently needed for early OC diagnosis. Liquid biopsies have been considered as a new noninvasive and promising method, using plasma/serum, uterine lavage, and urine samples for early cancer detection. We analyzed recent studies on molecular biomarkers with specific emphasis on liquid biopsy methods and diagnostic efficacy for OC through the detection of circulating tumor cells, circulating cell-free DNA, small noncoding RNAs, and tumor-educated platelets.
topic ovarian cancer
liquid biopsies
uterine lavage
high-throughput methods
NGS-based multigene panels
url https://www.mdpi.com/2072-6694/13/15/3840
work_keys_str_mv AT dianazilovic futurescreeningprospectsforovariancancer
AT rutaciurliene futurescreeningprospectsforovariancancer
AT rasasabaliauskaite futurescreeningprospectsforovariancancer
AT sonatajarmalaite futurescreeningprospectsforovariancancer
_version_ 1721218867130269696